RxDoctor Payments DataLook up a doctor →

David Greeley, MD

Neurology · Spokane, WANPI 1386758712

Payments from drug & device makers

$8,484,644in general payments, 2019–2025

Across 1,010 payments — averaging $8400.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$7M
  • Eli Lilly$1.1M
  • Eisai Inc.$227K
  • Merz North America, Inc.$52K
  • Teva Pharmaceuticals USA, Inc.$23K
  • Genentech, Inc.$14K
  • plus $32K from 52 others
$2,366in research payments, 2019–2025

Across 3 payments — averaging $788.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen75$7,012,924
Eli Lilly19$1,124,241
Eisai Inc.53$226,782
Merz North America, Inc.13$51,875
Teva Pharmaceuticals USA, Inc.163$23,486
Genentech, Inc.9$13,772
Ipsen Innovation7$8,544
H. Lundbeck A S1$4,500
E.r. Squibb & Sons, L.L.C.2$3,821
AbbVie(2 entities)165$3,035
Lilly USA, LLC73$1,488
Merz Pharmaceuticals, LLC39$1,475
Neurocrine Biosciences, Inc.37$760
Amgen(2 entities)31$673
Lundbeck LLC27$596
Neuronetics, Inc.6$512
Acadia Pharmaceuticals Inc21$478
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)22$451
Bristol Myers Squibb31$439
Genentech USA, Inc.7$319
Amneal Pharmaceuticals LLC15$318
Acorda Therapeutics, Inc10$278
Johnson & Johnson7$271
Otsuka America Pharmaceutical, Inc.15$260
Ipsen Biopharmaceuticals, Inc10$253
Novartis15$237
Sunovion Pharmaceuticals Inc.17$225
Pfizer10$224
Biohaven Pharmaceuticals, Inc.15$201
Upsher-smith Laboratories LLC11$200
Impel Pharmaceuticals Inc.10$196
AstraZeneca8$181
Novo Nordisk2$161
Argenx US, Inc.5$136
MDD US Operations, LLC3$124
Boston Scientific6$118
Revance Therapeutics, Inc.2$105
Sanofi6$105
Axsome Therapeutics, Inc.4$87
CSL Behring4$82
Banner Life Sciences, LLC3$68
Xeris Pharmaceuticals, Inc.3$68
Biohaven Pharmaceutical Holding Company Ltd.4$65
Supernus Pharmaceuticals, Inc.3$62
Cala Health, Inc.3$56
Takeda Pharmaceuticals U.S.A., Inc.2$55
Kyowa Kirin, Inc.3$48
Vanda Pharmaceuticals Inc.2$47
UCB, Inc.1$39
GE HealthCare2$38
Octapharma USA, Inc.1$34
SK Life Science, Inc.1$22
Otsuka Pharmaceutical Development & Commercialization, Inc.1$21
Avanir Pharmaceuticals, Inc.1$21
Alkermes, Inc.1$21
ANI Pharmaceuticals, Inc.1$20
Strongbridge US Inc.1$16
Kedrion Biopharma, Inc.1$12

How this compares

$8,484,644 in reported general payments places this provider in the 95th percentile of 418 neurology providers in Washington.

See all neurology providers in Washington →

Medicare billing

Part B allowed, 2024
$495,795
Medicare patients
455
Services billed
46,484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Spokane

See the full list for Washington →

Where these figures come from

Is this you, or does something look wrong? →